Technological Advancements in Fluorescence in Situ Hybridization Imaging Fuel Europe Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market
FISH imaging systems are witnessing a remarkable evolution due to the surge in technological advancements, which result in cutting-edge innovations transforming the landscape of genetic research and diagnostics. These advancements include enhanced optics, more sensitive and versatile fluorophores, and sophisticated automation features. Modern FISH imaging systems, integrated with these upgraded features, offer greater sensitivity, improved image resolution, and faster processing times. Moreover, these technological advancements have extended the application scope of FISH imaging from cancer diagnosis to genetic predisposition testing. In July 2021, BioView and Capio Biosciences collaborated to create a platform for collecting circulating tumor cells (CTCs) from whole blood. By integrating their technologies, these companies further worked on improving the CTC liquid biopsy downstream analysis. Similarly, BioView and Capio Biosciences, in collaboration, partnered with RUBYnanomed in December 2020 to create a unique imaging solution to accelerate the acceptance and adoption of CTC technology in clinics to enhance cancer detection. Thus, technological advancements in FISH imaging systems create significant opportunities for companies in the fluorescence in situ hybridization (FISH) imaging systems market.Europe Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market Overview
The Europe fluorescence in-situ hybridization (FISH) imaging systems market in Europe is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the global market. The European Europe Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market is expected to grow significantly during the forecast period due to the strong medical device manufacturing capabilities and high cancer prevalence in different European countries. Germany is one of the most lucrative medical device markets across the world. According to International Trade Administration (ITA), the German medical device market accounts for ~US$ 35.8 billion annually or 25.6% of the total European medical device market. As per ITA, Germany is the third-largest medical technology market in the world after the US and Japan and is by far the largest European market.Catering to the largest population in Europe, Germany's healthcare sector is a highly attractive sector with significant growth opportunities. A steady increase in life expectancy levels has led to a rise in cases of cancer and chronic and age-related illnesses. According to the data from The World Bank, in 2022, approximately 22% of Germans are aged 65 and above and prone to at least one chronic disease; this percentage is slightly higher than in any other European country. According to World Cancer Research Fund (WCRF) International, Germany had a significant incidence age-standardized rate of 281.9 cancer cases per 100,000, with 538,140 new cases in 2020. Additionally, as per GLOBOCAN 2020, Germany has a high prevalence rate of breast, prostate, lung, and colorectum cancer. Improved health awareness due to the prevalence of chronic diseases and cancer has increased the demand for diagnostics systems. Thus, the adoption of fluorescence in-situ hybridization (FISH) imaging systems is growing rapidly in Germany due to the flourishing medical device R&D landscape and rising cancer cases.
Europe Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market Revenue and Forecast to 2030 (US$ Million)
Europe Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market Segmentation
The Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented into product, application, end users and country.Based on product, the Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented into instruments, consumables, accessories, and software. The consumables segment held the largest share of the Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022.
In terms of application, the Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented into cancer diagnosis, genetic disease diagnosis, infectious disease diagnostic, and others. The cancer diagnosis segment held the largest share of the Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022.
Based on end user, the Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented into diagnostic laboratories, contract research organizations, pharmaceutical and biotechnological companies, and others. The diagnostic laboratories segment held the largest share of the Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022.
By country, the Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented int o Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany dominated the Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022.
Euroclone SpA, TissueGnostics GmbH, Agilent Technologies Inc, Abnova Taiwan Corp, BioGenex Laboratories Inc, Leica Biosystems Nussloch GmbH, MetaSystems Probes GmbH, Bio-View Ltd, Thermo Fisher Scientific Inc, and Applied Spectral Imaging are some of the leading companies operating in the Europe fluorescence in-situ hybridization (FISH) imaging systems market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe fluorescence in-situ hybridization (FISH) imaging systems market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in Europe fluorescence in-situ hybridization (FISH) imaging systems market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
Companies Mentioned
- Euroclone SpA
- TissueGnostics GmbH
- Agilent Technologies Inc
- Abnova Taiwan Corp
- BioGenex Laboratories Inc
- Leica Biosystems Nussloch GmbH
- MetaSystems Probes GmbH
- Bio-View Ltd
- Thermo Fisher Scientific Inc
- Applied Spectral Imaging